Orgenesis Inc (NASDAQ:ORGS) CEO Vered Caplan tells Proactive Investors the cell therapy development company has inked a collaboration and licensing deal with ExcellaBio Ltd for exosome-related technologies, in addition to a recent collaboration agreement with Digilab Inc to develop a live cell printing process and systems to automate the production of 3D cell and tissue structures.
View full ORGS profile View Profile
June 28 2019
June 17 2019
April 11 2019
April 04 2019